Small-molecule, tubulin-binding compounds as vascular targeting agents

Bibliography

• CONNELL RD, BEEBE JS: Patent focus on cancer chemotherapeutics: angiogenesis agents, IV: April 2001 - August 2001. Expert Opin. Ther. Patents (2001) 11(12):1919–1945.
   Web of Science ®Google Scholar
• GRIGGS J, METCALFE JC, HESKETH R: Targeting tumour vasculature: the development of combretastatin A4. Lancet Oricol. (2001) 2:82–87.
   PubMed Web of Science ®Google Scholar
• ••An interesting and comprehensive review ofCA4.
   Google Scholar
• Oxigene announces successful completion of its Phase I US trial of combretastatin A4P for the treatment of solid tumors. BW HealthWiCe (October 31, 2001).
   Google Scholar
• Oxigene expands drug development pipeline with next generation vascular targeting agent Oxi4503. Data presented at British Institute of Radiology meeting. BW HealthWire (Dec. 14, 2001). [At the time of this writing, the structure of Oxi 4503 is unknown.]
   Google Scholar
• HAMEL E, LIN CM: Interactions of combretastatin, a new plant-derived antimitotic agent, with tubulin. Biochem. Pharmacol. (1983) 32(24):3864–3867.
   PubMed Web of Science ®Google Scholar
• GRIGGS J, HESKETH R, SMITH GA et al.: Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue. Br .j Cancer (2001) 84(6)832–835.
   Google Scholar
• •An investigation demonstrating the breadth of the antivascular effect of CA4.
   Google Scholar
• MILLER KD, SWEENEY CJ, SLEDGE GW: Redefining the target: chemotherapeutics as antiangiogenics. Clin. °rico]. (2001) 19(4):1195–1206.
   Google Scholar
• CORREIA JJ, LOBERT S: Physiochemical aspects of tubulin-interacting antimitotic drugs. Curr. Pharm. Des. (2001) 7(13):1213–1228.
   PubMed Web of Science ®Google Scholar
• HAIT WN, RUBIN E, GOODIN S: Tubulin targeting agents. Cancer Chemother. Biol. Response Modil: (2001) 19:59–83.
   PubMedGoogle Scholar
• FOJO T, GIANNAKAKOU P: Taxol and other microtubule-interactive agents Curr. Opin. Oncol. Endocr. Metab. Invest. Drugs (2000) 2(3):293–304.
   Google Scholar
• TARABOLETTI G, MARGOSIO B: Antiangiogenic and antivascular therapy for cancer. Curr. Opin. Pharmacol. (2001) 1(4):378–384.
   Google Scholar
• PETTIT GR, SINGH SB, HAMEL E, LIN CM, ALBERTS DS, GARCIA-KENDALL D: Isolation and structure of the strong cell growth and trubulin inhibitor combretastatin A-4. Experientia (1989) 45(2):209–211.
   PubMedGoogle Scholar
• CHAPLIN DJ, PETTIT GR, HILL SA: Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res. (1999) 19:189–196.
   PubMed Web of Science ®Google Scholar
• TOZER GM, PRISE VE, WILSON J et al.: Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. (1999) 59(7):1626–1634.
   PubMed Web of Science ®Google Scholar
• ••An investigation showing that CA4 has adifferential effect in tumor tissues versus normal tissues.
   Google Scholar
• LANDUYT W, VERDOES O, DARIUS DO etal.: Vascular targeting of solid tumors: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. Eur. I Cancer. (2000) 36(14):1833–1843.
   Google Scholar
• TOZER GM, PRISE VE, WILSON J et al.: Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. (2001) 61:6413–6421.
   PubMed Web of Science ®Google Scholar
• ••A further investigation into the mechanismof CA4 and the influence of combination with an NO synthase inhibitor.
   Google Scholar
• BEAUREGARD DA, HILL SA, CHAPLIN DJ, BRINDLE KM: The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res. (2001) 61:6811–6815.
   PubMed Web of Science ®Google Scholar
• DARK GG, HILL SA, PRISE VE, TOZER GM, PETTIT GR, CHAPLIN DJ: Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. (1997) 57(10):1829–1834.
   PubMed Web of Science ®Google Scholar
• PETTIT GR, TEMPLE C, NARAYANAN VL et al.: Antineoplastic agents. 322. Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des. (1995) 10(4):299–309.
   Google Scholar
• PETTIT GR, RHODES MR: Antineoplastic agents. 389. New syntheses of the combretastatin A-4 prodrug. Anticancer Drug Des.(1998) 13(3):183–191.
   Google Scholar
• PARKINS CS, HOLDER AL, HILL SA, CHAPLIN DJ, TOZER GM: Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br. j Cancer (2000) 83(6) 811–816.
   Google Scholar
• SMITH KA, HILL SA, BEGG AC, DENEKAMP J: Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumors. Br. j Cancer (1988) 57:247–253.
   PubMed Web of Science ®Google Scholar
• CUSHMAN M, NAGARATHNAM D, GOPAL D, CHAKRABORTI AK, LIN CH, HAMEL E: Synthesis and evaluation of stilbene and dihydrostilbene derivatives as potential anticancer agents that inhibit tubulin polymerization. j Med. Chem. (1991) 34(8):2579–2588.
   PubMed Web of Science ®Google Scholar
• OHSUMI K, NAKAGAWA R, FUKUDA Yet al.: Novel combretastatin analogues effective against murine solid tumors: design and structure activity relationships. I Med. Chem. (1998) 41(16):3022–3032.
   Google Scholar
• WOODS JA, HADFIELD JA, PETTIT GR, FOX BW, MCGOWN AT: The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br Cancer (1995) 71(4):705–711.
   Google Scholar
• RAPOPORT H, WILLIAMS AR, CISNEY ME: Synthesis of dl-colchinol methyl ether. Am. Chem. Soc. (1950) 72:3324–3325.
   Google Scholar
• LEITER J, DOWNING V, HARTWELL JL, SHEAR MJ: Damage induced in sarcoma 37 with chemical agents. III. colchicine derivatives related to trimethylcolchicinic acid and colchinol. Natl. Cancer Inst. (1952) 13:379–392.
   Google Scholar
• ZD-6126. Pharmaprojects.
   Google Scholar
• PINNEY KG, BOUNDS AD, DINGEMAN KM et al.: A new anti-tubulin agent containing the benzorb]thiophene ring system. Bioorg. Med. Chem. Lett. (1999) 9(8):1081–1086.
   Google Scholar
• JONES CK, JEVNIKAR MG, PIKE AJ et al.: Antiestrogens. 2. Structure activity studies in a series of 3-aroy1-2-arylbenzorb]thiophe derivatives leading to [6-hydroxy 2 (4 hydroxyphenyObenzo-rb]thien-3-yl] [4- [2-(1-piperidinyl)ethoxy1-phenyl[methanone hydrochloride (LY156758), a remarkably effective estrogen antagonist with only minimal intrinsic estrogenicity. I Med. Chem. (1984) 27(8):1057–1066.
   Google Scholar
• D'AMATO RJ, LIN CM, FLYNN E, FOLKMAN J, HAMEL E: 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc. Nati Acad. Sci. USA (1994) 91(9):3964–3968.
   Google Scholar
• PINNEY KG, CHEN Z, MOCHARLA VP, CHOONY N, STRONG T.: Synthesis of berm° thiophene-based vAscular Targeting Prodrug and Related Anti-tubulin Ligands. 220th ACS Meeting, Washington, D.C. USA (2000). ORG196.
   Google Scholar
• FLYNN BL, FLYNN GP, HAMEL E, JUNG MK: The synthesis and tubulin binding activity of thiophene-based analogues of combretastatin A-4. Bioorg. Med. Chem. Lett. (2001) 11:2341–2343.
   PubMed Web of Science ®Google Scholar
• MAHBOOBI S, PONGRATZ H, HERWIG H et al: Synthetic 2-aroylindole derivtives as a new class of potent tubulin-inhibitory, antimitotic agents. j Med. Chem. (2001) 44(26):4535–4553.
   PubMed Web of Science ®Google Scholar
• MEDARDE M, RAMOS A, CABALLERO E: Synthesis and pharmacological activity of diarylindole derivatives. Cytotoxic agents based on combretastatins. Bioorg. Med. Chem. Lett. 1999 9:2303–2308.
   PubMedGoogle Scholar
• DENEKAMP J: Combining antivascular approaches with radiotherapy. A perspective. Basic Clin. Oncol. (2001) 24:579–595.
   Google Scholar
• LANDUYT W, AHMED B, NUYTS S et al.: In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int. Radiat. Oncol Biol. Phys. (2001) 49(2):443–450.
   PubMed Web of Science ®Google Scholar
• MURATA R, OVERGAARD J, HORSMAN MR: Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy. mt. I Radiat. amyl. Biol. Phys. (2001) 49(4):1018–1024.
   Google Scholar